Peripheral inflammation found to drive Parkinson's, shifting drug targets
A newly identified mechanism where peripheral inflammation spreads to the brain could reshape how European pharmaceutical companies approach Parkinson’s disease treatments.
An international team of scientists has found that Parkinson’s disease may be driven by systemic inflammation that spreads to the brain, rather than originating solely within the central nervous system.
The research, published in Cell Reports, demonstrates that aging or the most common genetic cause of Parkinson’s—the G2019S mutation—causes a cell's own DNA to leak into its cytosol. This triggers a chronic immune response via the cGAS-STING pathway, which is then exported to the brain through tiny, DNA-carrying extracellular vesicles.
For Europe’s pharmaceutical and biotech sectors, this finding alters the investment calculus for neurodegenerative drug development. Historically, designing treatments for brain diseases has been hampered by the difficulty of penetrating the blood-brain barrier. If Parkinson’s is driven by peripheral immune signaling, developers can target the systemic source of the inflammation instead.
The study provides clear validation for two specific molecular targets. In human blood samples, an LRRK2 inhibitor successfully normalized elevated interferon levels in monocytes from Parkinson’s patients. In mouse models, deleting STING entirely reversed the inflammatory response in both the spleen and brain, protecting the animals from motor decline and preventing the loss of 51% of dopaminergic neurons.
The researchers also mapped a timeline showing that peripheral inflammation precedes brain damage. In the mouse models, the systemic inflammatory signature appeared at three months, while brain inflammation and motor decline did not emerge until 12 months. The mutant mice developed increased blood-brain barrier permeability, explaining how the peripheral signals ultimately crossed into the central nervous system.
The researchers confirmed this pathway in human patients, who exhibited elevated DNA-containing vesicles in both their blood and cerebrospinal fluid. When applied to laboratory cells, these patient-derived vesicles induced a STING-dependent inflammatory response.
As European governments grapple with the rising economic costs of an aging population, so-called inflammaging has become a critical public health challenge. A therapeutic strategy focused on intercepting peripheral inflammation before it reaches the brain could significantly reduce the clinical trial failure rate in Parkinson's research, potentially delivering more effective treatments to market faster.
